Are we creating a new phenotype? Physiological barriers and ethical considerations in the treatment of hereditary transthyretin-amyloidosis
Abstract Hereditary transthyretin (TTR) amyloidosis (ATTRv) is an autosomal dominant, systemic disease transmitted by amyloidogenic mutations in the TTR gene. To prevent the otherwise fatal disease course, TTR stabilizers and mRNA silencing antisense drugs are currently approved treatment options. W...
Guardado en:
Autores principales: | Maike F. Dohrn, Jessica Medina, Karmele R. Olaciregui Dague, Ernst Hund |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
BMC
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/9fb44f289ffd423bb7e7aa14a4bebefc |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Oligonucleotides
Publicado: (2003) -
Epidemiology of variant transthyretin amyloidosis at a reference center in Argentina
por: Maria S. Saez, et al.
Publicado: (2021) -
Retinitis pigmentosa associated with systemic light chain amyloidosis (AL amyloidosis)
por: Salem Bouomrani, et al.
Publicado: (2021) -
Polyglutamine Ataxias: Our Current Molecular Understanding and What the Future Holds for Antisense Therapies
por: Craig S. McIntosh, et al.
Publicado: (2021) -
Subcutaneous scalp nodule as the presenting symptom of systemic light-chain amyloidosis
por: Joseph Tadros, et al.
Publicado: (2018)